ABSTRACT
OBJECTIVES: To compare results after stimulation with corifollitropin alfa (Elonva) in unselected group of women entering for the first time in in vitro fertilization programme (IVF) with results from Phase III randomized trials with selected groups of women. DESIGN: Prospective study. SETTING: Sanatorium Pronatal, Praha. METHODS: 40 unselected women with adequat ovarian reserve entering for the first time in IVF programme were stimulated with corifollitropin alfa and GnRH antagonists. Avarage age in the study group was 32,8 years (29-42 years), women younger then 36 and less then 60 kg received Elonva 100 µg , all others (age > 36 let, weight > 60 kg) Elonva 150 µg. Five days after egg retrieval one blastocyst was transferred (single embryo transfer - eSET). Our results were compared with the resuls in higly selected groups of women from Phase III randomized trials. RESULTS: After stimulation with corifollitropin alfa and GnRH antagonists on average 10,6 (9,2 ± 4,2) eggs could be retrieved, among them 7,3 (6,6 ± 3,9) were M II oocytes (68,9%) and fertilisation rate was 84,6%. After first embryo transfer ("fresh" embryos and embryos from "freeze all" cycles) 14 pregnancies were achieved (37,8%), three pregnancies were achieved later from transfer of frozen-thawed embryos (cumulative pregnancy rate 45,9%). There were three abortions. No severe hyperstimulation syndrom occured. Our results in unselected group of women stimulated for the first in an IVF programme with corifollitropin alfa are fully comparable with results published in randomized trials with selected group of patiens. CONCLUSION: Corifollitropin alfa in combination with daily GnRH antagonist can be successfully used in normal-responder patients stimulated for the first time in an IVF programmeKeywords: corifollitropin alfa, GnRH antagonists, ovarian stimulation, pregnancy.
Subject(s)
Fertility Agents, Female/administration & dosage , Fertilization in Vitro/methods , Follicle Stimulating Hormone, Human/administration & dosage , Infertility/therapy , Ovulation Induction/methods , Adult , Female , Follicle Stimulating Hormone, Human/blood , Humans , Pregnancy , Pregnancy Rate , Prospective Studies , Treatment OutcomeABSTRACT
OBJECTIVE: To demonstrate successful restoration of ovarian function after ovarian transplantation in young woman with premature ovarian failure after gonadotoxic treatment of breast carcinoma and to discuss its possibilities. DESIGN: Case report. SETTING: Sanatorium Pronatal, Prague. CASE REPORT: We demonstrate successful ovarian transplantation and restoration of ovarian function in 33 years old woman after cryopreservation of ovarian tissue performed before chemotherapy and radiotherapy of breast carcinoma and discuss possibilities of this approach in women diagnosed with cancer and subsequent risk of ovarian silure. CONCLUSION: Cryopreservation of ovarian tissue is one of efficient options to preserve fertility in young patients facing gonadotoxic treatment.
Subject(s)
Antineoplastic Agents/adverse effects , Breast Neoplasms/drug therapy , Cryopreservation , Fertility Preservation/methods , Ovary/transplantation , Primary Ovarian Insufficiency/surgery , Adult , Female , Humans , Primary Ovarian Insufficiency/chemically induced , Transplantation, AutologousABSTRACT
The present study compares distribution and elimination characteristics of 111In-DTPA-D-Phe1-octreotide and 111In-DTPA-L-Phe1-octreotide in rats and evaluated the effect of the replacement of the terminal L-phenylalanine by D-phenylalanine on pharmacokinetic profiles of the radiolabelled peptides. Both agents exhibited rapid radioactivity clearance from the blood and most organs and tissues with no systematic and significant differences in activity accumulation. The long-term retention and high radioactivity concentrations for both compounds under study were found in the kidneys and organs with a high density of somatostatin receptors, such as the pancreas and adrenals. The residence times in these organs were longer for 111In-DTPA-D-Phe1-octreotide in comparison with 111In-DTPA-L-Phe1-octreotide. The major elimination pathway for both radiolabelled peptides was relatively rapid excretion into the urine. Analysis of the renal handling by an employment of the perfused rat kidney showed that both peptides were eliminated mainly by the mechanism of glomerular filtration. Rat liver perfusion experiments confirmed a very low value of bile clearance of radioactivity for both agents under study.
Subject(s)
Octreotide/analogs & derivatives , Octreotide/pharmacokinetics , Pentetic Acid/analogs & derivatives , Pentetic Acid/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Animals , Bile/chemistry , Indium Radioisotopes , Injections, Intravenous , Kidney/metabolism , Liver/metabolism , Male , Octreotide/chemistry , Octreotide/urine , Pentetic Acid/chemistry , Pentetic Acid/urine , Radiopharmaceuticals/chemistry , Radiopharmaceuticals/urine , Rats , Rats, Wistar , Stereoisomerism , Tissue DistributionABSTRACT
Changes in the pharmacokinetics and metabolism of sodium salicylate were studied in rabbits with acute renal damage induced by intravenous administration of uranyl nitrate in the dose of 0.2 mg/kg. In the pathological group there occurs a marked decrease in elimination characteristics, the total plasma clearance of salicylate linearly decreasing with a decrease in the value of glomerular filtration rate. The plasma levels of creatinine and urea are suitable indices for the estimation of the changes in the plasma binding of salicylate. An increase in the fraction of free salicylate in the plasma of rabbits with acute impairment of the kidney results in a not very conclusive increase in the size of distributional volumes. In the control group mainly the unchanged drug is excreted into urine, whereas in rabbits with acute renal damage salicylate metabolites represent the majority of the eliminated amount.
